Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients

World Journal of Surgery

Volumn 31, Issue 2, 2007, Pages 276-289

  Yildirim, Emin ^a,b   Berberoglu, Ugur ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BIOASSAY; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT ASSESSMENT; PREDICTION; PREDICTOR VARIABLE; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 33846565308     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0487-5     Document Type: Article

References (83)

1. Hadjiloucas I, Bundred NJ. Axillary surgery: is it necessary? Breast 2000;9:2-4.
2. Bembenek A, Schlag PM. Lymph node dissection in breast cancer. Langenbecks Arch Surg 2000;385:236-245.
3. Canavese G, Catturich A, Vecchio C, et al. Prognostic role of lymph node level involvement in patients undergoing axillary dissection for breast cancer. Eur J Surg Oncol 1998;24:104-109.
4. Vin-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in breast cancer. Breast Cancer Res 2004;6:R680-R688.
5. Toma S, Leonessa F, Romanini A, et al. Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer. Anticancer Res 1991;11:1439-1444.
6. Newman LA, Kuerer HM, Fornage B, et al. Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg 2001;181:313-318.
7. Barth RJ, Danforth DN, Venzon DJ, et al. Level of axillary involvement by lymph node metastases from breast cancer is not an independent predictor of survival. Arch Surg 1991;126:574-577.
8. Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997;15:691-700.
9. Luini A, Zurrida S, Galimberti V, et al. Axillary dissection in breast cancer. Crit Rev Oncol Hematol 1999; 30:63-70.
10. Sinha PS, Thrush S, Bendall S, et al. Does radical surgery to the axilla give a survival advantage in more severe breast cancer? Eur J Cancer 2002;38:1474-1477.
11. Voss M, Schneider JW, Apffelstaedt J. Axillary lymph node involvement in stage III breast cancer: treatment implications. J Surg Oncol 1999;71:162-166.
12. Greene FL, Page DL, Fleming ID, et al. editors. AJCC Cancer Staging Manuel. 6th ed. Berlin Heidelberg New York: Springer, 2002.
13. Megale Costa LJ, Soares HP, Gaspar HA, et al. Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304-306.
14. Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006-2014.
15. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Cox DR. Regression models and life tables. J R Stat Soc 1972;B34:187-220.
17. Kleinbaum DG, Kupper LL, Muller KE, et al. editors. Applied Regression Analysis and Other Multivariable Methods, 3rd edn. Pacific Grove: Brooks/Cole, 1998.
18. Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer: Berlin Heidelberg, New York.
19. Schemper M. Predictive accuracy and explained variation. Stat Med 2003;22:2299-2308.
20. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver characteristic (ROC) curve. Radiology 1982;143:29-36.
21. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.
22. Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2-6.
23. Jansen RLH, Hillen HFP, Schouten HC. Prognostic and predictive factors in breast cancer. Netherlands J Med 1997;51:65-77.
24. Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005;91:11-18.
25. Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer. Acta Oncol 2000;39:455-466.
26. Saha S, Farrar WB, Young DC, et al. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol 2000;73:134-137.
27. Recht A. Nodal treatment for patients with early stage breast cancer: guilty or innocent? Radiother Oncol 1992;25:79-82.
28. Yildirim E, Soydinc P, Yildirim N, et al. Role of increased arterial inflow in arm edema after modified radical mastectomy. J Exp Clin Cancer Res 2000;19:427-430.
29. Chua B, Ung O, Taylor R, et al. Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 2002;72:786-792.
30. Petrek JA, Heelan MC. Incidence of breast carcinoma related lymphedema. Cancer 1998;83:2776-2781.
31. Liljegren G, Holmberg L. Arm morbidity after sector resection, axillary dissection with or without postoperative radiotherapy in breast cancer stage I: results from a randomized trial - Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer 1997;33:193-199.
32. Kuehn T, Klas W, Darsow M, et al. Long-term morbidity following axillary dissection in breast cancer patients: clinical assessment, significance for life quality and the impact of demographic, oncologic, and therapeutic factors. Breast Cancer Res Treat 2000;64:275-286.
33. Taylor KO. Morbidity associated with axillary surgery for breast cancer. ANZ J Surg 2004;74:314-317.
34. Somner JEA, Dixon JMJ, Thomas JSJ. Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol 2004;57:845-848.
35. Blichert-Toft M. Axillary surgery in breast cancer management. Acta Oncol 2000;39:269-275.
36. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:1415-1418.
37. Petrik DW, McCready DR, Sawka CA, Goel V. Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer. J Surg Oncol 2003;82:84-90.
38. Cady B. A contemporary view of axillary dissection. Ann Surg 2000;232:8-9.
39. Rutgers EJ. EUSOMA Consensus GroupQuality control in the locoregional treatment of breast cancer. Eur J Cancer 2001;37:447-453.
40. Rutgers EJ. Guidelines to assure quality in breast cancer surgery. Eur J Surg Oncol 2005;31:568-576.
41. Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol 1998;5:140-149.
42. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001;19:3817-3827.
43. Goldhirsch A, Glick JH, Gelber RD. panel members Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
44. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1539-1569.
45. Kingsmore DB, Ssemwogerere A, Hole DJ, et al. Increased mortality from breast cancer and inadequate axillary treatment. Breast 2003;12:36-41.
46. Gervasoni JE, Taneja C, Chung MA, et al. Axillary dissection in the context of the biology of lymph node metastases. Am J Surg 2000;180:278-283.
47. Pierce LJ. The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 2005;23:1706-1717.
48. Recht A, Gray R, Davidson NE, et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:1689-1700.
49. Senofsky GM, Moffat FL, Davis K, et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991;126:1336-1342.
50. Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early stage breast cancer. An analysis of 259 consecutive patients. Arch Surg 1990;125:1144-1147.
51. Arriagada R, Rutqvist LE, Mattsson A, et al. Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 1995;13:2869-2878.
52. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b Trial. N Eng J Med 1997;337:949-955.
53. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Eng J Med 1997;337:956-962.
54. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group 82c randomized trial. Lancet 1999;353:1641-1648.
55. Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220-1229.
56. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst 2005;97:116-126.
57. Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicine-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000;18:2817-2827.
58. Beenken SW, Urist MM, Zhang Y, et al. Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003;237:732-739.
59. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med 2002;347:1233-1241.
60. Deckers PJ. Axillary dissection in breast cancer: when, why, how much, and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217-219.
61. Henderson IC. Axillary surgery: clinical judgment required. J Clin Oncol 2006;24:325-326.
62. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival: a Bayesian metaanalysis. Ann Surg Oncol 1999;61:109-116.
63. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-2106.
64. Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
65. Olivotto IA, Truong PT. Postmastectomy radiation therapy: who needs it? J Clin Oncol 2004;22:4237-4239.
66. Parmigiani G, Berry DA, Winer EP, et al. Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis. J Clin Oncol 1999;17:1465-1473.
67. Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000;88:608-614.
68. Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: Dissection or radiotherapy? Results of a randomized study with 15 years of follow up. J Clin Oncol 2004;22:97-101.
69. Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 2001;50:735-742.
70. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I Through VII. J Clin Oncol 2003;21:1205-1213.
71. Voogd AC, Nielsen M, Peterse JL, et al. Danish Breast Cancer Cooperative Group and the Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19:1688-1697.
72. Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicine-based chemotherapy and postmastectomy implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003;57:336-344.
73. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy. Results of five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials. J Clin Oncol 2004;22:4247-4254.
74. Jager JJ, Volovics L, Schouten LJ, et al. Locoregional recurrences after mastectomy in breast cancer: prognostic factors and implications for postoperative irradiation. Radiother Oncol 1999;50:267-275.
75. Fisher BJ, Perera FE, Cooke AL, et al. Long-term follow-up axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence. Int J Radiat Oncol Biol Phys 1997;38:541-550.
76. Cheng JCH, Chen CM, Liu MC, et al. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:980-988.
77. Gruber G, Bonetti M, Nasi ML, et al. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol 2005;23:7089-7097.
78. Katz A, Buchholz TA, Thames H, et al. Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implication for adjuvant irradiation. Int J Radiat Oncol Biol Phys 2001;50:397-403.
79. van der Wal BCH, Butzelaar RMJM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481-489.
80. Voordeckers M, Vinh-Hung V, Van de Sten J, et al. The lymph node ratio as prognostic factor in node positive breast cancer. Radiother Oncol 2004;70:225-230.
81. Haris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999;44:989-990.
82. van der Hage JA, Putter H, Bonnema J, et al. EORTC Breast Cancer Group Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 2003;39:2192-2199.
83. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 2004;240:306-312.